Outcomes after neoadjuvant treatment with gemcitabine and erlotinib followed by gemcitabine–erlotinib and radiotherapy for resectable pancreatic cancer (GEMCAD 10-03 trial)-Reference-Cited by-同舟云学术

Outcomes after neoadjuvant treatment with gemcitabine and erlotinib followed by gemcitabine–erlotinib and radiotherapy for resectable pancreatic cancer (GEMCAD 10-03 trial)

Published:2018-09-17 Issue:6 Volume:82 Page:935-943
ISSN:0344-5704
Container-title:Cancer Chemotherapy and Pharmacology
language:en
Short-container-title:Cancer Chemother Pharmacol

Author:

Maurel Joan,Sánchez-Cabús Santiago,Laquente Berta,Gaba Lydia,Visa Laura,Fabregat Joan,Povés Ignacio,Roselló Susana,Díaz-Beveridge Roberto,Martín-Richard Marta,Rodriguez Javier,Sabater Luis,Conill Carles,Cambray María,Reig Ana,Ayuso Juan Ramón,Valls Carlos,Ferrández Antonio,Bombí Josep Antoni,Ginés Angels,García-Albéniz Xabier,Fernández-Cruz Laureano

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology

Link

http://link.springer.com/article/10.1007/s00280-018-3682-9/fulltext.html

Reference46 articles.

1. Varadhachary GR, Wolff RA, Crane CH et al (2008) Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head. J Clin Oncol 26:3487–3495

2. OʼReilly EM, Perelshteyn A, Jarnagin WR et al (2014) A single-arm, nonrandomized phase II trial of neoadjuvant gemcitabine and oxaliplatin in patients with resectable pancreas adenocarcinoma. Ann Surg 260:142–148

3. Heinrich S, Schäfer M, Weber A et al (2008) Neoadjuvant chemotherapy generates a significant tumor response in resectable pancreatic cancer without increasing morbidity: results of a prospective phase II trial. Ann Surg 248:1014–1022

4. White RR, Hurwitz HI, Morse MA et al (2001) Neoadjuvant chemoradiation for localized adenocarcinoma of the pancreas. Ann Surg Oncol 8:758–765

5. Snady H, Bruckner H, Cooperman A, Paradiso J, Kiefer L (2000) Survival advantage of combined chemoradiotherapy compared with resection as the initial treatment of patients with regional pancreatic carcinoma. An outcomes trial. Cancer 89:314–327

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The trend toward more target therapy in pancreatic ductal adenocarcinoma;Expert Review of Anticancer Therapy;2024-05-23

2. Executive Summary of the American Radium Society Appropriate Use Criteria for Neoadjuvant Therapy for Nonmetastatic Pancreatic Adenocarcinoma;American Journal of Clinical Oncology;2023-12-22

3. Defining the Optimal Duration of Neoadjuvant Therapy for Pancreatic Ductal Adenocarcinoma;Pancreas;2022-10

4. Trends in Preoperative Chemotherapy Utilization for Proximal Pancreatic Cancer: Are We Making Progress?;Journal of Gastrointestinal Surgery;2022-05-04

5. Immunotherapy in pancreatic cancer—an emerging role: a narrative review;Chinese Clinical Oncology;2022-02